Lyell Immunopharma, Inc. Operating Lease Cost
Lyell Immunopharma, Inc. (LYEL) reported Operating Lease Cost of $2.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-06
- Lyell Immunopharma, Inc. operating lease, cost for the quarter ending 2026-06-30 was $2.00M, a 16.67% decline year-over-year.
- Lyell Immunopharma, Inc. operating lease, cost for the quarter ending 2026-03-31 was $2.10M, a 12.50% decline year-over-year.
- Lyell Immunopharma, Inc. operating lease, cost for the quarter ending 2025-12-31 was $2.10M, a 12.50% decline year-over-year.
- Lyell Immunopharma, Inc. operating lease, cost for the quarter ending 2025-09-30 was $2.20M, a 0.00% change year-over-year.
- Lyell Immunopharma, Inc. operating lease, cost for fiscal 2025 was $9.10M, a 1.09% decline from fiscal 2024.
- Lyell Immunopharma, Inc. operating lease, cost for fiscal 2024 was $9.20M, a 2.22% increase from fiscal 2023.
- Lyell Immunopharma, Inc. operating lease, cost for fiscal 2023 was $9.00M, a 3.23% decline from fiscal 2022.
- Lyell Immunopharma, Inc. operating lease, cost for fiscal 2022 was $9.30M, a 1.06% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.00M 10-Q · filed 2026-08-06 | $4.10M 10-Q · filed 2026-08-06 | $6.20M derived: sum of 3 quarters · filed 2026-08-06 | $8.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.10M 10-Q · filed 2026-05-06 | $4.20M derived: sum of 2 quarters · filed 2026-05-06 | $6.40M derived: sum of 3 quarters · filed 2026-05-06 | $8.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.30M derived: sum of 2 quarters · filed 2026-03-12 | $6.70M derived: sum of 3 quarters · filed 2026-08-06 | $9.10M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.20M 10-Q · filed 2025-11-12 | $4.60M derived: sum of 2 quarters · filed 2026-08-06 | $7.00M 10-Q · filed 2025-11-12 | $9.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.40M 10-Q · filed 2026-08-06 | $4.80M 10-Q · filed 2026-08-06 | $7.20M derived: sum of 3 quarters · filed 2026-08-06 | $9.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.40M 10-Q · filed 2026-05-06 | $4.80M derived: sum of 2 quarters · filed 2026-05-06 | $7.00M derived: sum of 3 quarters · filed 2026-05-06 | $9.30M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.60M derived: sum of 2 quarters · filed 2026-03-12 | $6.90M derived: sum of 3 quarters · filed 2026-03-12 | $9.20M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.20M 10-Q · filed 2025-11-12 | $4.50M derived: sum of 2 quarters · filed 2025-11-12 | $6.80M 10-Q · filed 2025-11-12 | $9.10M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $2.30M 10-Q · filed 2025-08-12 | $4.60M 10-Q · filed 2025-08-12 | $6.90M derived: sum of 3 quarters · filed 2026-03-12 | $9.20M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-13 | $4.60M derived: sum of 2 quarters · filed 2026-03-12 | $6.90M derived: sum of 3 quarters · filed 2026-03-12 | $9.20M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.60M derived: sum of 2 quarters · filed 2026-03-12 | $6.90M derived: sum of 3 quarters · filed 2026-03-12 | $9.00M 10-K · filed 2026-03-12 |
| 2023-09-30 | $2.30M 10-Q · filed 2024-11-07 | $4.60M derived: sum of 2 quarters · filed 2024-11-07 | $6.70M 10-Q · filed 2024-11-07 | $9.00M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $2.30M 10-Q · filed 2024-08-07 | $4.40M 10-Q · filed 2024-08-07 | $6.70M derived: sum of 3 quarters · filed 2025-03-11 | $9.00M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $2.10M 10-Q · filed 2024-05-06 | $4.40M derived: sum of 2 quarters · filed 2025-03-11 | $6.70M derived: sum of 3 quarters · filed 2025-03-11 | $8.90M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $4.60M derived: sum of 2 quarters · filed 2025-03-11 | $6.80M derived: sum of 3 quarters · filed 2025-03-11 | $9.30M 10-K · filed 2025-03-11 |
| 2022-09-30 | $2.30M 10-Q · filed 2023-11-07 | $4.50M derived: sum of 2 quarters · filed 2023-11-07 | $7.00M 10-Q · filed 2023-11-07 | $9.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $2.20M 10-Q · filed 2023-08-08 | $4.70M 10-Q · filed 2023-08-08 | $7.00M derived: sum of 3 quarters · filed 2024-02-28 | $9.40M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $2.50M 10-Q · filed 2023-05-04 | $4.80M derived: sum of 2 quarters · filed 2024-02-28 | $7.20M derived: sum of 3 quarters · filed 2024-02-28 | $9.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.70M derived: sum of 2 quarters · filed 2024-02-28 | $7.10M derived: sum of 3 quarters · filed 2024-02-28 | $9.40M 10-K · filed 2024-02-28 |
| 2021-09-30 | $2.40M 10-Q · filed 2022-11-08 | $4.80M derived: sum of 2 quarters · filed 2022-11-08 | $7.10M 10-Q · filed 2022-11-08 | $10.10M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $2.40M 10-Q · filed 2022-08-04 | $4.80M 10-Q · filed 2022-08-04 | $7.70M derived: sum of 3 quarters · filed 2023-02-28 | $10.60M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $2.40M 10-Q · filed 2022-05-10 | $5.30M derived: sum of 2 quarters · filed 2023-02-28 | $8.20M derived: sum of 3 quarters · filed 2023-02-28 | $11.10M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.80M derived: sum of 2 quarters · filed 2023-02-28 | $8.70M derived: sum of 3 quarters · filed 2023-02-28 | $11.20M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.90M 10-Q · filed 2021-11-12 | $5.80M derived: sum of 2 quarters · filed 2021-11-12 | $8.30M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.90M 10-Q · filed 2021-08-12 | $5.40M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | $4.60M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |